Research ArticleCancer

A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma

See allHide authors and affiliations

Science Translational Medicine  07 Apr 2021:
Vol. 13, Issue 588, eaaz6804
DOI: 10.1126/scitranslmed.aaz6804

Article Information

vol. 13 no. 588

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication October 4, 2019
  • Resubmitted September 26, 2020
  • Accepted for publication March 5, 2021
  • .

Author Information

  1. Weiqin Yang1,,
  2. Yu Feng1,,
  3. Jingying Zhou1,2,,
  4. Otto Ka-Wing Cheung1,
  5. Jianquan Cao1,
  6. Jing Wang1,
  7. Wenshu Tang1,
  8. Yalin Tu1,
  9. Liangliang Xu1,
  10. Feng Wu2,
  11. Zhiwu Tan3,4,
  12. Hanyong Sun5,
  13. Yuan Tian6,
  14. John Wong7,
  15. Paul Bo-San Lai7,
  16. Stephen Lam Chan8,9,
  17. Anthony Wing-Hung Chan2,
  18. Patrick Boon-Ooi Tan10,11,12,13,14,15,
  19. Zhiwei Chen3,4,
  20. Joseph Jao-Yiu Sung16,17,18,
  21. Kevin Yuk-Lap Yip19,
  22. Ka-Fai To2,9 and
  23. Alfred Sze-Lok Cheng1,*
  1. 1School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.
  2. 2Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.
  3. 3AIDS Institute, The University of Hong Kong, Hong Kong SAR 999077, China.
  4. 4Department of Microbiology and Research Center for Infection and Immunity, The University of Hong Kong, Hong Kong SAR 999077, China.
  5. 5Department of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.
  6. 6Guangdong Key Laboratory for Genome Stability and Human Disease Prevention, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Shenzhen University Health Science Center, Shenzhen 518061, China.
  7. 7Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.
  8. 8Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.
  9. 9State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.
  10. 10Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore 169857, Singapore.
  11. 11Cancer Science Institute of Singapore, National University of Singapore, Singapore 117599, Singapore.
  12. 12Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Singapore 138672, Singapore.
  13. 13SingHealth/Duke-NUS Institute of Precision Medicine, National Heart Centre Singapore, Singapore 169857, Singapore.
  14. 14Cellular and Molecular Research, National Cancer Centre, Singapore 169610, Singapore.
  15. 15Singapore Gastric Cancer Consortium, Singapore 119228, Singapore.
  16. 16Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 639798, Singapore.
  17. 17State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.
  18. 18Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.
  19. 19Department of Computer Science and Engineering, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.
  1. *Corresponding author. Email: alfredcheng{at}cuhk.edu.hk
  • These authors contributed equally to this work.

Altmetric

Article usage

Article usage: April 2021 to April 2021

AbstractFullPdf
Apr 20214210597419

Stay Connected to Science Translational Medicine